Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Mathias Rummel(Universitätsklinikum Gießen und Marburg), Juergen Barth(Justus-Liebig-Universität Gießen), Martina Stauch, Christina Balser(Philipps University of Marburg), Michael Sandherr, Frank Kauff(Justus-Liebig-Universität Gießen), Ulrich von Gruenhagen(Praxis für Hämatologie und Onkologie), Ulrich Kaiser(University of Applied Sciences Landshut), Axel Hinke, N. Niederle(Klinikum Leverkusen), Lothar Mueller(Leibniz Centre for Agricultural Landscape Research), Wolfgang Blau(Universitätsklinikum Gießen und Marburg), Wolfram Brugger(University of Freiburg), Eckhart Weidmann(Krankenhaus Nordwest), Hans-Peter Boeck, Manfred Welslau(Klinikum Aschaffenburg), Lars Hahn(Gesellschaft für Klinische Forschung), Christoph Losem, Julia Vereshchagina(Justus-Liebig-Universität Gießen)
The Lancet Oncology
December 4, 2015
10.1016/s1470-2045(15)00447-7
Cited by 155

Related Papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|European Journal of Cancer|2011|615
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
|Blood|2010|485
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425